Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in wild type, accelerating drug discovery for sporadic neurodegenerative diseases.


SynAging will be present at the following meetings in 2018:

Neuro4D Meeting June 4-5, Mainz, Germany

AAIC Meeting July 22-26, Chicago, USA

Society for Neuroscience Meeting November 3-7, San Diego, USA

SynAging' past meetings in 2017:

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt Main, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies Meeting in Athens, September 7-10, 2017

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings:

Press & Publications

SynAging's Poster won the 'Best Poster Award' here during the '20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies' meeting in Athens, September 7-10, 2017 entitled:
Download PDF

Download PDF

Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance;  Link

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease

Download PDF

Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF


In vivo Models of Sporadic Alzheimer's Disease

ICV injection:

This page contains the following readouts:

 A single intracerebroventricular (icv) injection of amyloid-β oligomers (AβO) in normal mice of various ages induces cognitive defects within few days. In our full cognitive evaluation of the mouse model we investigate induced neurodegeneration in:

  • Short term memory (Y-maze)
  • Learning (Morris water maze, MWM)
  • Long term memory (MWM)
  • Memory formation (novel object recognition, NOR)
  • Spatial memory (spatial recognition test, SRT)
  • Global behavior (Open-field)

Groups of 10 WT mice, or more, are treated by a single icv injection of minute amounts of AβO and investigated for the improvements by symptomatic drug candidates, or for the neuroprotective effects of disease modifying drug candidates. Drug treatments can be preventive, given before AβO treatment, or curative, given after or during AβO treatment. Possible routes of administration are: po, sc, or ip, or once icv or iv.


One possible experimental cycle is performed in a minimum of 14 days, as given below:

Y-Maze Model of Alzheimer's Disease:

Automatic Y-Maze Observation and Evaluation

The Y-maze model is largely established in cognitive investigations and uses the natural behavior of rodents to alternate between choices on subsequent trials. However, such alternation requires short-term memory of the previous choice and attention to the task and is largely dependent on the pre-frontal cortex. Rodents with strong cognitive impairment will show random behavior.

Already four days after the single icv injection of Aβ oligomers (AβO) the mice show significant changes in the Y-maze assay, which persist for up to three month (max. lenght of investigation). The same mice can be investigated on a weekly basis in logitudinal studies:


  • Typically reduction of alternation behavior close to the random 50%
  • Partially reverted by e.g. Donepezil (Aricept®), a clinically approved cholinesterase inhibitor


Product Sheet “Mouse Y-Maze Assay”, Download PDF, 500 KB

Product Sheet “FAST Symptomatic and Neuroprotection Screen”, Download PDF, 530 KB


Morris Water Maze Model of Sporadic Alzheimer's Disease:

Automatic Observation in MWM

The Morris water maze is another widely accepted cognition model, investigating spatial learning and (long-term) topographical memory, largely dependent on hippocampal function. Mice are trained to find a platform hidden under the opaque water surface in multiple trials. Their learning performance in recalling the platform location is based on visual clues and video recorded. Their learning speed, which is the steadily reduced time from their release into the water until finding the platform, is investigated over multiple days.

For analyzing their long-term memory, the test is repeated multiple days after training: the platform is taken away and the number of crossings over the former platform location, or the time of the first crossing, are used as measures to investigate their long-term memory.

The light blue circle shows the location of the platform. The pool is divided in four quadrants. In yellow, the swimming trajectory of a vehicle injected control mouse is shown. In red, the pathway of an AβO injected mouse is depicted.



Product Sheet “Mouse Full Cognition Enhancement AD Assay”, Download PDF, 510 KB

Novel Object Recognition Model of Sporadic Alzheimer's Disease


The Novel Object Recognition model utilizes the normal behavior of rodents to investigate novel objects for a significantly longer time than known objects, largely dependent on perirhinal cortex function. Mice or rats are icv injected with vehicle or SynAging’s amyloid-β 1-42 oligomer preparation (AβO) on day 0 and can be treated with symptomatic or disease modifying drug candidates before and after that date. The NOR assay can be performed multiple times in longitudinal studies to investigate disease modification after drug wash-out.

On day four, or later, after icv injection, the mice or rats are allowed to explore two identical objects in the acquisition trial. Following a short inter-trial interval, one of the objects is replaced by a novel object. The animals are returned to the arena and the time spent actively exploring each object is recorded. Normal rodents recall the familiar object and will spend significantly more time exploring the novel object. In contrast, AβO treated rodents exhibit clear cognitive impairment and will spend a similar amount of time investigating both the 'familiar' and 'novel' object. This can be transiently reversed with known clinical cognitive enhancers (e.g. donepezil).

This assay has been built-up and validated at SynAging for mice (product sheet below) and rats (graphs above) at a partner site. SynAging will always organize, coordinate and report the evaluation of your test items in this model.

Product Sheet “Mouse NOR Screen”, Download PDF, 480 KB


Spacial Recognition Test (SRT), a Quick Test of Hippocampal Function

Topographical memory (TM) is the ability to recall the contours, design, shape, or structure of a surrounding, and linked to hippocampal function. TM is disrupted during the early stages of Alzheimer’s disease and the SRT is sensitive to drugs used for Alzheimer’s disease treatment.

SynAging uses a two-chamber apparatus for SRT, in which both chambers differ in shape, pattern and color (i.e. are topographically different). The two compartments are connected by a clear Plexiglas corridor. No habituation is necessary. SynAging validated the disruption of TM in the SRT by amyloid-β oligomers (AbO). In comparison to the well established Morris Water-Maze, SRT is also hippocampus-dependent, but does not involve a learning component, making it fast, cost effective and allowing longitudinal studies.

Evaluation of test compound mediated improvement of hippocampal function is performed in the SRT assay. In the figure above, the results are presented for day 15: vehicle injected control mice can differentiate between familiar and novel chamber, whereas AβO-injected mice do not differentiate, as they lost the memory of the familiar chamber. Humanin, co-injected with AβO, can rescue the AβO-induced cognitive decline. This assay can be performed multiple times in longitudinal studies, e.g. to differentiate disease modifying versus symptomatic effects.

Product Sheet “Mouse Spatial Recognition Test”, Download PDF, 450 KB